Promising Korea? CMO giant Samsung Biologics opens doors to Biopharma-Reporter

By Dan Stanton

- Last updated on GMT

We visited Samsung Biologics in Sangdo, Incheon last month, expected to be the largest biologics site in the world by 2018
We visited Samsung Biologics in Sangdo, Incheon last month, expected to be the largest biologics site in the world by 2018

Related tags Samsung biologics Bristol-myers squibb

Since 2011, Samsung Biologics has built two plants, gained Bristol-Myers Squibb and Roche as clients and launched an IPO. With a third facility under construction, Biopharma-Reporter visited to see the CMO’s ambition in action.

South Korea is becoming a biopharma powerhouse, according to experts at last month’s CPhI event​ in Seoul, who cite both the number of drugs being developed there and the investments being made in bioproduction as growth drivers.

One firm with a willingness to invest in manufacturing capacity is Samsung Biologics, which invited Biopharma-Reporter to visit the plant it is building in Songdo, Incheon.

The $740m plant – which will be Samsung’s third facility at the site – will house 180,000L of capacity in twelve 15,000L stainless steel bioreactors.

Doing the math(s), when the plant comes online in 2018, Samsung Biologics will boast a total of 360,000L of biomanufacturing capacity across the Songdo site; 50% more than Genentech has at its Vacaville, California​ site and 50,000L more than Celltrion plans​ to have down the road. 

Combined with Celltrion’s planned capacity upgrade, this will give the reclaimed region of Songdo​ the most concentrated biomanufacturing capacity in the world. Not bad for an area of land which only twenty years ago formed part of the Yellow Sea.

The new Samsung Biologics plant is being built by another wing of the Korean multinational conglomerate, Samsung Engineering, and as construction will be complete next year, all this journalist could report back with is a crane-heavy photo of the project’s progress.

samsung bio 1
Commissioned last December, the third facility is expected to be complete in 2017 with production commencing the following year

Site visit

Samsung recently filed for an IPO on the Korean stock exchange. Listing rules mean the firm can only share limited information with the press, even invited journalists.

As a result, security was tight during our visit to Samsung’s second plant in Songdowhich started making drugs earlier this year.

Phones, laptops, cameras, dictaphones, USB sticks, hard drives and – for some reason – portable games systems cannot be taken beyond the reception desk.

samsung bio 2
No cellphones, laptops or cameras... even if they are Samsung made!

The tour began with a marketing video beamed out on a Samsung television and was followed by a virtual reality stroll around the upstream production hall using a – you guessed it – a Samsung Gear VR headset and Samsung Galaxy phone.

The facility – which was commissioned in 2013​ - houses 150,000L of bioreactor capacity in ten stainless steel vessels supplied by Swiss firm Bioengineering AG.

Products made at the site include Yervoy (ipilimumab), Bristol-Myers Squibb’s advanced melanoma treatment, which was approved in the US in 2011​.

Samsung Biologics signed a ten-year service agreement to make the monoclonal antibody in 2013, and – the following year – extended its partnership​ with the Big Pharma firm. The CMO also makes drugs for Swiss pharma giant Roche​ at the site.


When Samsung Biologics launched the IPO last month​, Benepali – a biosimilar version of Amgen’s Enbrel owned by Samsung Bioepis - was named as its ‘main’ product (see prospectus here​, in Korean).

This, we were told, is down to Samsung Biologics’ 91% ownership of Samsung Bioepis – the other 9% being owned by Biogen – rather than the CMO’s manufacturing revenue from the monoclonal antibody.

In fact Biopharma-Reporter learned that despite a string of regulatory successes for Bioepis (the latest in Canada this week​), the facility is not yet making product for its sister company.

While the IPO meant Samsung could not say much, the scale of the firm’s ambition is clear.

Banners adorn the site of Samsung Biologics’ goal of being the world’s top CMO by 2020.

But with Biopharma’s growing demand for manufacturing capacity coupled with Samsung Biologics’ rapid rise since its creation in 2011, it seems to this reporter that the firm could be challenging this title as soon as the third plant comes online in 2018.

samsung bio 3
Samsung Biologics' message '2020 CMO Champion' is omnipresent across the Incheon site

Related news

Show more

Related products

show more

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Product Brochure

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Related suppliers

Follow us